Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the naphthalenes class, with the molecular formula C16H16N4O3S and a molecular weight of approximately 344.39 g/mol[1][2][3]. It is also known by code names such as CHEMBL321944 and uPa_13. The compound has been studied primarily as an experimental inhibitor of urokinase-type plasminogen activator (uPA), an enzyme involved in processes like tissue remodeling, cancer metastasis, and fibrinolysis[3]. There are no approved indications or clinical trials reported for this molecule, and it remains at the preclinical/experimental stage[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-methoxy-8-[1-(methylsulfonyl)-1h-pyrazol-4-yl]naphthalene-2-carboximidamide.